Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Inventory (2022 - 2025)

Historic Inventory for Immunocore Holdings (IMCR) over the last 4 years, with Q3 2025 value amounting to $5.7 million.

  • Immunocore Holdings' Inventory rose 2516.6% to $5.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.7 million, marking a year-over-year increase of 2516.6%. This contributed to the annual value of $5.4 million for FY2024, which is 2099.53% up from last year.
  • Latest data reveals that Immunocore Holdings reported Inventory of $5.7 million as of Q3 2025, which was up 2516.6% from $5.5 million recorded in Q2 2025.
  • Immunocore Holdings' 5-year Inventory high stood at $6.8 million for Q1 2025, and its period low was $692000.0 during Q4 2022.
  • For the 4-year period, Immunocore Holdings' Inventory averaged around $4.5 million, with its median value being $4.5 million (2024).
  • Its Inventory has fluctuated over the past 5 years, first soared by 55043.35% in 2023, then soared by 2099.53% in 2024.
  • Over the past 4 years, Immunocore Holdings' Inventory (Quarter) stood at $692000.0 in 2022, then skyrocketed by 550.43% to $4.5 million in 2023, then rose by 21.0% to $5.4 million in 2024, then grew by 3.84% to $5.7 million in 2025.
  • Its last three reported values are $5.7 million in Q3 2025, $5.5 million for Q2 2025, and $6.8 million during Q1 2025.